South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...

Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named ...

US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...

Kazia Therapeutics faces a setback as the FDA deems accelerated approval for brain cancer drug paxalisib unlikely despite ...

California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo ...

Regeneron acquires UK-based Oxular, adding ocular delivery technology and Phase II therapy OXU-001 for diabetic macular edema ...

Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...

Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

WuXi Biologics has signed a deal with Sino Biopharm to develop a first-in-class monoclonal antibody targeting an undisclosed ...

One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics ...